These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 35405113)

  • 1. Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway.
    Wu L; Liang J; Li J; Xu Y; Chen J; Su Y; Xian Y; Wei J; Xu J; Zhao J; Liu Q; Yang Y
    Eur J Pharmacol; 2022 May; 923():174908. PubMed ID: 35405113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca
    Zou B; Zheng J; Deng W; Tan Y; Jie L; Qu Y; Yang Q; Ke M; Ding Z; Chen Y; Yu Q; Li X
    Phytomedicine; 2021 Jan; 80():153377. PubMed ID: 33126167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
    Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
    Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity.
    Lin X; Yuan G; Yang B; Xie C; Zhou Z; Liu Y; Liu Z; Wu Z; Akimoto Y; Li N; Xu R; Song F
    Phytomedicine; 2024 Jul; 129():155559. PubMed ID: 38579642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
    Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
    Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption.
    Li S; Teguh D; Wu D; Liu L; Hu C; Yuan J; Inderjeeth CA; Xu J
    J Cell Physiol; 2023 Aug; 238(8):1823-1835. PubMed ID: 37334837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anethole inhibits RANKL-induced osteoclastogenesis by downregulating ERK/AKT signaling and prevents ovariectomy-induced bone loss in vivo.
    Qu H; Zhang Y; He R; Lin N; Wang C
    Int Immunopharmacol; 2021 Nov; 100():108113. PubMed ID: 34530203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (-)-Epicatechin 3-O-β-D-allopyranoside prevent ovariectomy-induced bone loss in mice by suppressing RANKL-induced NF-κB and NFATc-1 signaling pathways.
    Hsiao HB; Wu JB; Lin WC
    BMC Complement Altern Med; 2017 May; 17(1):245. PubMed ID: 28468652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cumambrin A prevents OVX-induced osteoporosis
    Zhou L; Liu Q; Hong G; Song F; Zhao J; Yuan J; Xu J; Tan RX; Tickner J; Gu Q; Xu J
    FASEB J; 2019 Jun; 33(6):6726-6735. PubMed ID: 30807230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
    Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
    Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca
    Zeng X; Zhang Y; Wang S; Wang K; Tao L; Zou M; Chen N; Xu J; Liu S; Li X
    Biochem Pharmacol; 2017 Jan; 124():57-68. PubMed ID: 27789216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy-induced bone loss.
    Xian Y; Gao Y; Su Y; Su Y; Lian H; Feng X; Liu Z; Zhao J; Xu J; Liu Q; Song F
    Phytother Res; 2024 Apr; 38(4):1971-1989. PubMed ID: 38358727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
    Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S
    Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
    Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
    Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
    [No Abstract]   [Full Text] [Related]  

  • 19. New mechanistic understanding of osteoclast differentiation and bone resorption mediated by P2X7 receptors and PI3K-Akt-GSK3β signaling.
    Lu J; Shi X; Fu Q; Han Y; Zhu L; Zhou Z; Li Y; Lu N
    Cell Mol Biol Lett; 2024 Jul; 29(1):100. PubMed ID: 38977961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obacunone inhibits RANKL/M-CSF-mediated osteoclastogenesis by suppressing integrin- FAK-Src signaling.
    Hu H; Wang X; Huang Y; He B; Zhu J; Sun K; Deng C; Guo Y; Hao D; Jian B
    Cytokine; 2023 Apr; 164():156134. PubMed ID: 36804257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.